Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement

Int J Clin Oncol. 2003 Dec;8(6):391-4. doi: 10.1007/s10147-003-0349-1.

Abstract

Although T-prolymphocytic leukemia (T-PLL) is characterized by organ infiltration, small-intestinal involvement is rare. We performed an unrelated allogeneic bone marrow transplantation in a patient with T-PLL who had multiple lymphomatous polyposis of the small intestine refractory to combination chemotherapy (cyclophosphamide, vincristine, and prednisolone [COP] and fludarabine plus cyclophosphamide). The patient developed no graft-versus-host disease (GVHD) and remains in complete remission 16 months after the transplantation. T-PLL is usually refractory to chemotherapy and is a T-cell malignancy with poor prognosis. There have been several reports on allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for T-PLL, but none on allo-HSCT for T-PLL patients with intestinal involvement. It is suggested that allo-HSCT may improve the prognosis in patients with T-PLL involving the small intestine.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation*
  • Cyclophosphamide / administration & dosage
  • Drug Resistance, Neoplasm
  • Humans
  • Intestinal Polyposis / etiology*
  • Intestinal Polyposis / pathology
  • Leukemia, Prolymphocytic / complications*
  • Leukemia, Prolymphocytic / therapy*
  • Leukemia, T-Cell / complications*
  • Leukemia, T-Cell / therapy*
  • Male
  • Prednisone / administration & dosage
  • Transplantation, Homologous
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives*
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
  • Prednisone

Supplementary concepts

  • COP protocol 2